AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

The toxicity of dose-intensive regimens used for Burkitt lymphoma prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients. We added rituximab, reduced and/or rescheduled cyclo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Noy, Ariela, Lee, Jeannette Y., Cesarman, Ethel, Ambinder, Richard, Baiocchi, Robert, Reid, Erin, Ratner, Lee, Wagner-Johnston, Nina, Kaplan, Lawrence
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2015
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4497960/
https://ncbi.nlm.nih.gov/pubmed/25957391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-623900
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi